Changing Pharmaceutical Regulatory Landscape in China and Asia - The Dynamics and Outlook of the ASEAN Regulatory Landscape

The ASEAN region has the 5th largest GDP globally. The growing workforce, higher foreign direct investments and greater economic integration have underpinned the region’s recent rise. The region continues to have higher projected growth rates than that of the global economy and is expected to be one of the strongest consumer markets by 2030. This presents an ideal environment for pharmaceutical businesses to thrive in. While the regional authorities have been collaborating to find synergies amongst the countries; they need to focus on the training and development of skilled workforce and strive for higher alignment amongst local regulatory bodies to realize the full potential of the region.